Antibody Information
General Information of This Antibody
| Antibody ID | ANI0RSZBP |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-CLDN18.2 mAb SYSA-1801 |
|||||
| Synonyms |
Anti-CLDN18.2 SYSA-1801 mAb; Anti-CLDN18.2 SYSA-1801 mAb
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SYSA-1801 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
47.10% (gastric cancer)
33.30% (1.00 mg/kg) 40.00% (2.00 mg/kg) 100.00% (2.50 mg/kg) 20.00% (3.00 mg/kg) 38.10% (all) |
|||
| Patients Enrolled |
Patients with resistant/refractory solid tumors that express CLDN18.2 who progressed on or were intolerant to standard treatment, or had no standard treatment were recruited.. ECOG score of 0-2.
|
||||
| Administration Dosage |
0.50 up to 3.00 mg/kg on day 1, administered once every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05009966 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 trial to evaluate safety, tolerability, pharmacokinetics, immunogenicity and initial efficacy of SYSA1801 in the treatment of CLDN 18.2 positive advanced malignant solid tumor.
|
||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.